Literature DB >> 24445562

Biosimilar competition: lessons from Europe.

Henry Grabowski1, Rahul Guha2, Maria Salgado2.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24445562     DOI： 10.1038/nrd4210

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  24 in total

1.  Core Concepts: Biosimilars.

Authors:  Stephen Ornes
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-15       Impact factor: 11.205

2.  History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.

Authors:  Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2017-02-01       Impact factor: 3.754

3.  Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population.

Authors:  Steven Kozlowski; Noy Birger; Stephaeno Brereton; Stephen J McKean; Michael Wernecke; Leah Christl; Jeffrey A Kelman
Journal:  JAMA       Date:  2018-09-04       Impact factor: 56.272

4.  Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.

Authors:  François Bocquet; Anaïs Loubière; Isabelle Fusier; Anne-Laure Cordonnier; Pascal Paubel
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

5.  Biosimilars: Still Not Quite Ready for Prime Time.

Authors:  Martha M Rumore; F Randy Vogenberg
Journal:  P T       Date:  2016-06

6.  Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists.

Authors:  Sadia Shakeel; Mohamed Azmi Hassali; Hina Rehman; Anees Ur Rehman; Jaya Muneswarao
Journal:  Int J Gen Med       Date:  2020-11-11

7.  Barriers to the uptake of biosimilars and possible solutions: a Belgian case study.

Authors:  Pieter Dylst; Arnold Vulto; Steven Simoens
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

8.  Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products.

Authors:  Morgane C Mouslim; Antonio J Trujillo; G Caleb Alexander; Jodi B Segal
Journal:  Value Health       Date:  2020-10-23       Impact factor: 5.725

9.  A systematic review of the factors associated with the initiation of biologicals in patients with rheumatological conditions.

Authors:  Wan Yu Png; Yu Heng Kwan; Ka Keat Lim; Eng Hui Chew; Nai Lee Lui; Chuen Seng Tan; Truls Østbye; Julian Thumboo; Warren Fong
Journal:  Eur J Hosp Pharm       Date:  2018-05-02

Review 10.  Biosimilar insulins: a European perspective.

Authors:  J H DeVries; S C L Gough; J Kiljanski; L Heinemann
Journal:  Diabetes Obes Metab       Date:  2014-11-27       Impact factor: 6.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.